Results 41 to 50 of about 63,602 (218)

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis

ClinicoEconomics and Outcomes Research, 2021
Marco Bellone,1 Lorenzo Pradelli,1 Stefano Molica,2 Adele Emanuela De Francesco,3 Daniela Ghislieri,4 Emanuele Guardalben,5 Antonietta Caputo4 1Department of Health Economics and Outcome Research, AdRes Health Economics and Outcomes Research, Turin ...
Bellone M, Pradelli L, Molica S, De Francesco AE, Ghislieri D, Guardalben E, Caputo A   +6 more
doaj  

Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali

Drugs in R&D, 2020
Background In 2006, the National Malaria Control Program in Mali recommended artemisinin-based combination therapy as the first-line treatment for uncomplicated malaria.
Karim Traoré, Seidina A. S. Diakité, Sekou Bah, Drissa S. Konaté, Djeneba Dabitao, Ibrahim Sanogo, Modibo Sangaré, Souleymane Dama, Bourama Keita, Mory Doumbouya, Merepen A. Guindo, Seydou Doumbia, Mahamadou Diakité   +12 more
doaj   +1 more source

A Bayesian approach to stochastic cost-effectiveness analysis [PDF]

, 2001
The aim of this paper is to discuss the use of Bayesian methods in cost-effectiveness analysis (CEA) and the common ground between Bayesian and traditional frequentist approaches.
Briggs, A.
core  

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane, Giorgia Coratti, Chiara Cutrì, Antonio Varone, Riccardo Masson, Adele D'Amico, Valeria Sansone, Sonia Messina, Federica Ricci, Chiara Ticci, Claudio Bruno, Caterina Agosto, Francesca Benedetti, Antonella Pini, Sabrina Siliquini, Massimiliano Filosto, Alberto Zambon, Ilaria Bitetti, Maria Rosaria Manna, Claudia Dosi, Riccardo Zanin, Stefano Parravicini, Roberto De Sanctis, Giulia Stanca, Michela Catteruccia, Michele Tosi, Irene Mizzoni, Emilio Albamonte, Valentina Franchino, Maria Sframeli, Ilaria Cavallina, Elena Procopio, Michele Sacchini, Simone Morando, Noemi Brolatti, Federica Trucco, Gaia Scarpini, Elena Briganti, Beatrice Berti, Concetta Palermo, Daniela Leone, Stefano C. Previtali, Eugenio Mercuri, the ITASMAC working group   +43 more
wiley   +1 more source

Performance of IRS on malaria prevalence and incidence using pirimiphos-methyl in the context of pyrethroid resistance in Koulikoro region, Mali

Malaria Journal, 2020
Background Koulikoro Health District is one of three districts of Mali where the indoor residual spray (IRS) has been implemented from 2008 to 2016. With widespread of resistance to pyrethroid, IRS was shifted from pyrethroid to pirimiphos-methyl from ...
Fousseyni Kané, Moussa Keïta, Boïssé Traoré, Sory Ibrahim Diawara, Sidy Bane, Souleymane Diarra, Nafomon Sogoba, Seydou Doumbia   +7 more
doaj   +1 more source

Evaluating Value-Based Frameworks Used for Relapsed or Refractory Multiple Myeloma Regimens: ICER Report, ASCO Value Framework, and NCCN Evidence Blocks [PDF]

, 2017
BACKGROUND: With the continuous rise in costs for oncology drugs, the Institute for Clinical and Economic Review (ICER), the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have developed value-based ...
Chun, PharmD, Grace, Djatche, PharmD, Laurence M., Goble, PharmD, Joseph, Varga, PharmD, Stefan   +3 more
core   +1 more source

Economic evaluation: what does a nurse manager need to know?

, 2005
This paper considers how health economists can assist nurse managers, using the concepts and tools of economic evaluation. We aim to clarify these and also explode some of the myths about economic evaluation and its role in health care decision-making ...
Douglas, Hannah-Rose, Normand, Charles
core   +1 more source

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. [PDF]

, 2019
BackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.MethodsTo illustrate ...
Chen, Bingshu E, Dewa, Carolyn S, Hay, Annette, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Jonker, Derek, Leighl, Natasha B, Mittmann, Nicole, O'Callaghan, Chris, Pater, Joseph, Thavorn, Kednapa, Trenaman, Logan, Tu, Dongsheng   +12 more
core   +1 more source

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

Arthritis Care &Research, EarlyView.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer, Rui Xiao, Andrew Grossman, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +5 more
wiley   +1 more source

ОЦЕНКА КЛИНИКО-ФАРМАКОЭКОНОМИЧЕСКОЙ ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ РЕЦИДИВИРУЮЩЕГО БАКТЕРИАЛЬНОГО ВАГИНОЗА

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta
Введение. Рецидивирующий бактериальный вагиноз (БВ) ассоциирован с частыми повторными курсами терапии и значимой нагрузкой на бюджет здравоохранения.
Д. Э. Станько
doaj   +1 more source